EKF Diagnostics Holdings PLC Director/PDMR Shareholding (2293W)

TIDMEKF

RNS Number : 2293W

EKF Diagnostics Holdings PLC

22 April 2021

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Sale of shares by a Director

The Board of EKF Diagnostics Holdings plc (AIM: EKF) has been informed that on 20 April 2021 Christopher Mills, Chairman, sold a total of 3,963,591 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at an average price of 80 pence per Ordinary Share.

Following this transaction, Christopher Mills' total direct and indirect interest in the Group is 132,150,000 Ordinary Shares representing approximately 29.04% of the Group's total issued share capital.

The Notification of Dealing Form required in accordance with UK MAR is set out below.

 
     EKF Diagnostics Holdings plc                                        www.ekfdiagnostics.com 
     Christopher Mills, Non-executive Chairman                        Tel: [phone] 
     Julian Baines, CEO 
     Richard Evans, FD & COO 
 
     N+1 Singer                                                              Tel: [phone] 
     Aubrey Powell / George Tzimas (Corporate 
      Finance) 
      Tom Salvesen (Corporate Broking) 
 
     Walbrook PR Limited                        Tel: [phone] or [e-mail] 
     Paul McManus / Lianne Cawthorne                   Mob: [phone] 
                                                                                        391 303 
 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.

EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
     1         Details of the person discharging managerial responsibilities 
                / person closely associated 
     a)        Name                                    Christopher Mills 
          --------------------------------------  ----------------------------------------- 
     2         Reason for the notification 
          --------------------------------------------------------------------------------- 
     a)        Position/status                         Non-Executive Chairman 
          --------------------------------------  ----------------------------------------- 
     b)        Initial notification                    Initial Notification 
                /Amendment 
          --------------------------------------  ----------------------------------------- 
     3         Details of the issuer, emission allowance market participant, 
                auction platform, auctioneer or auction monitor 
          --------------------------------------------------------------------------------- 
     a)        Name                                    EKF Diagnostics Holdings plc 
          --------------------------------------  ----------------------------------------- 
     b)        LEI                                     213800DXTF3EAUK1AR05 
          --------------------------------------  ----------------------------------------- 
     4         Details of the transaction(s): section to be repeated 
                for (i) each type of instrument; (ii) each type of transaction; 
                (iii) each date; and (iv) each place where transactions 
                have been conducted 
          --------------------------------------------------------------------------------- 
     a)        Description of the                      Ordinary shares of GBP0.01 each 
                financial instrument, 
                type of instrument 
 
               Identification code                     GB0031509804 
 
     b)        Nature of the transaction               Sale of shares 
          --------------------------------------  ----------------------------------------- 
     c)        Price(s) and volume(s) 
                                                   ------------------  ------------------ 
                                                        Price(s)            Volume(s) 
                                                   ------------------  ------------------ 
                                                        0.80                3,963,591 
                                                   ------------------  ------------------ 
 
     d)        Aggregated information 
 
      - Aggregated volume                     N/A - Single Transaction 
 
      - Price 
 
     e)        Date of the transaction                 20 April 2021 
          --------------------------------------  ----------------------------------------- 
     f)        Place of the transaction                London Stock Exchange 
          --------------------------------------  ----------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBRGDSXXDDGBB

(END) Dow Jones Newswires

April 22, 2021 02:00 ET (06:00 GMT)